Agreements reached under this partnership
Capital and Business Alliance- 1
With a view to executing the definitive agreement for the product, the parties will confirm the basic economic and business terms, including the upfront payment, development milestones, post-commercialization royalties and supply of the product.
- 2
Following execution of the definitive agreement, 丸石製薬 will make an additional investment in クリングルファーマ.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
| Item | Details |
|---|---|
| Name of alliance partner | 丸石製薬株式会社 |
| Alliance partner's business activities | Built on business platforms in perioperative medicine, infection control and basic drugs, the company is also expanding into acute and emergency medicine and supportive care, including cancer supportive care. |
| Alliance partner's location | Osaka City, Osaka Prefecture |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | With a view to executing the definitive agreement for the product, the parties will confirm the basic economic and business terms, including the upfront payment, development milestones, post-commercialization royalties and supply of the product., Following execution of the definitive agreement, 丸石製薬 will make an additional investment in クリングルファーマ. |
| Contract Date | 15 July 2026 (Basic Agreement) |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The companies explained that they entered into the marketing partnership based on 丸石製薬's expertise and extensive experience as a specialty pharmaceutical company, as well as its domestic sales network.